Campath alemtuzumab humanized monoclonal antibody against CD52 regulatory update

The FDA's Oncologic Drugs Advisory Committee (ODAC) voted 14-1 to recommend accelerated approval of the partners' Campath to treat advanced B cell chronic lymphocytic leukemia (CLL) in patients who have been treated with alkylating agents and have failed fludarabine therapy (see BioCentury Extra, Thursday Dec. 14). ...